Reporting to the President, provide leadership direction and growth for the Toxicology Department focused on providing client-based laboratory services including, but not limited, to cGMP/GLP pharmacology, toxicology and pharmacokinetic testing.

Reporting to the President/CEO, responsible for leadership direction of drug discovery/exploratory development objectives focused on cancer-associated epigenetic targets. Strong emphasis on translational medicine development and implementation.Responsible for integration of efforts across Discovery functional groups including preclinical/non-clinical pharmacology, ADME/DMPK, Toxicology and Early Development (biomarkers and patient pre-selection)

Reporting to the President/Chief Scientific Officer, implement and direct in vivo profiling of lead oncology compounds targeting the AAA-ATPase VCP/p97 of the ubiquitin-proteasome complex.Manage a small team executing in-house in vivo pharmacology studies including PK/PD, efficacy, ADME/DMPK, non-GLP toxicology studies and biomarker validationDesign and manage preclinical studies characterizing pharmacodynamic/biomarker effects and other efficacy markers of lead compoundsDevelopment of Phase 1 pharmacodynamic/biomarker assaysManagement of outsourced studies including CRO/clinical trial central lab selection, contract negotiations, setting timelines, and budgeting

As department head, responsible for priortization and managment of multidisciplinary teams focused on internal pharmacology (PD, efficacy), pharmacokinetic, nonGLP toxicology, and discovery/clinical tissue-based biomarker research efforts evaluating novel oncology compounds Budget, design and coordinate external CRO studies for additional pharmacokinetic, pharmacodynamic and efficacy evaluation of lead compoundsForecast and maintain annual departmental budgetSuccessful recruitment and hiring of PhD/MS/BS personnelResponsible for AAALAC-accredited vivariaWriting, editing, and approval of departmental reports and other relevant documentation for internal and external efforts including development candidate nomination, IND and NDA pharmacology sections, and peer reviewed journal publicationsProject Team Leader for oncology and metabolism programs

Research scientist responsible for an in vivo group evaluating the pharmacology profile (PK, PD, efficacy, safety) of novel oncology compounds. Responsibilities included design and execution of tumor- and surrogate tissue-based PD models, implementation of solid tumor orthotopic/ectopic xenograft efficacy models, survival efficacy models, and metastasis models, and nonGLP safety evaluation

Research Assistant Professor (Carlos Arteaga MD Lab)*Explored the in vitro cellular signaling profile of Herceptin and other small molecule compounds*Identified p27 as a target of AKT, which mediates its cellular localization